GLP-1 agonists in addiction therapy – review
GLP-1 receptor agonists show promise in reducing alcohol consumption and cravings, as well as supporting nicotine abstinence. However, more research is needed for stimulant use disorders.
Cannabis in PTSD Treatment: Meta-Analysis of Trauma-Focused Care
Clinical Takeaway People with PTSD and co-occurring substance use disorders who also use cannabis can still benefit meaningfully from trauma-focused treatments, and cannabis use does not appear to undermine treatment effectiveness compared to non-users.…
Cannabis Use Disorder Carries Greater Psychiatric Risk in Adolescents Than Adults, Johns Hopkins Study Finds
"The relationship between cannabis use disorder and psychiatric outcomes is nuanced and varies significantly by age and comorbidity... These results should not be interpreted as cannabis being 'safe,' but rather that risk is relative and…
Neurologic Complications of Drug and Alcohol Use.
A comprehensive clinical review identifies emerging neurologic complications across substance classes, with particular attention to potential cannabis-stroke associations. The review provides neurologists with systematic approaches for recognizing…
Cannabinoid Clinical Trials: Mental Health Evidence
Clinical Takeaway Clinical Takeaway: Current randomized controlled trial evidence does not demonstrate established efficacy or safety of cannabinoids as primary treatment for mental disorders or substance use disorders. Existing research gaps mean…
Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study.
A large cohort study of US veterans found GLP-1 receptor agonists substance use disorder prevention benefits compared to other diabetes medications. This BMJ research suggests potential neurobiological effects beyond metabolic control, though causation…
Association of Cannabis Use Disorder Versus Other Substance Use Disorders With Psychiatric Conditions: A Propensity-Matched Retrospective Cohort Analysis.
The authors compared the risk of mental disorders between patients with cannabis use disorder (CUD) and those with other substance use disorders (SUDs). The ...
Endocannabinoid System and PTSD: Clinical Evidence
Clinical Takeaway Trauma-focused treatments for PTSD remain effective in patients with co-occurring cannabis use and substance use disorders, showing comparable outcomes to non-trauma-focused approaches. Current cannabis use does not appear to…
Endocannabinoid System Research: Cannabis Mental Health Care
Clinical Takeaway Cannabinoids show limited evidence for treating mental disorders and substance use disorders in controlled trials, with safety concerns that require further investigation. Current research does not support cannabinoids as a primary…
Endocannabinoid System Clinical Research Overview
Clinical Takeaway Cannabinoid treatments show limited evidence for mental health and substance use disorders in randomized controlled trials, with unclear safety profiles that require further investigation before clinical adoption. Current research does…